Core Viewpoint - The company, Furuida, is divesting its wholly-owned subsidiary, Shandong Lushang Yinzao Commercial Management Co., Ltd. (Yinzao Management), for 88.4028 million yuan to a related party, aiming to optimize resource allocation and focus on its core pharmaceutical and cosmetics businesses [1][5]. Group 1: Transaction Details - Furuida's board approved the transfer of 100% equity of Yinzao Management, which will no longer be included in the consolidated financial statements post-transaction [1]. - The transaction is classified as a related party transaction due to both parties being controlled by the same parent company, Shandong Provincial Commercial Group [1]. Group 2: Financial Performance of Yinzao Management - Yinzao Management's revenue primarily comes from managing internal real estate projects, but it has faced challenges due to state policies affecting state-owned capital's exit from the real estate sector [3]. - The company reported a net loss of 62.35 thousand yuan in 2024, which further increased to 87.68 thousand yuan in the first half of 2025 [3]. Group 3: Strategic Implications for Furuida - By divesting a loss-making non-core business, Furuida aims to reshape its competitive advantage and concentrate on its main sectors [5]. - The company has been actively restructuring, having previously divested eight real estate companies and related debts for a total of 5.901 billion yuan, resulting in a significant shift in revenue structure from real estate to zero [5]. - Despite focusing on pharmaceuticals and cosmetics, Furuida's performance has been under pressure, with a 7.05% decline in revenue to 1.79 billion yuan and a 15.16% drop in net profit to 108 million yuan in the first half of 2025 [5][6]. Group 4: Challenges in Core Business Segments - The decline in performance is attributed to the underperformance of the popular brand, Aier Doctor, which saw a 29.97% decrease in revenue to 451 million yuan in the first half of 2025 [6]. - The pharmaceutical segment also faced challenges, with a 13.87% revenue decline to 207 million yuan, impacted by the expansion of centralized procurement and price reductions of winning products [6].

Key Points - The revenue from products used for controlled nuclear fusion at Ha Huan Huatong accounts for less than 1% of total revenue [1] - Dongyangguang expects a net profit increase of 171.08% to 199.88% in the first three quarters [2] - Lianhua Holdings anticipates a net profit increase of 51.39% to 69.55% in the first three quarters [5] - Allwinner Technology projects a net profit growth of 72.2% to 92.06% year-on-year for the first three quarters [5] - Northern Rare Earth expects a net profit increase of 272.54% to 287.34% in the first three quarters [5] - Strong瑞 Technology's controlling shareholder and its concerted parties plan to reduce their holdings by no more than 3% [5] - East China Airlines Logistics' shareholder Tianjin Ruiyuan intends to reduce holdings by no more than 15.8756 million shares [5] - New Light Optoelectronics' actual controller and director Kang Lixin plans to increase holdings by 5 million to 10 million yuan [5] - Jiulian Technology plans to raise no more than 182 million yuan through a private placement [5] - Jingu Co. signed a strategic cooperation agreement with Ninebot [5]

Group 1 - Haheng Huadong's revenue from products used in controlled nuclear fusion accounts for less than 1% of total revenue [1] - Huayuan Technology plans to transfer 100% equity of Yinzou Commercial Management for 88.4028 million yuan to Lushang Furuida [1][2] - Dongyangguang expects a net profit increase of 171.08% to 199.88% in the first three quarters [1] Group 2 - Kangqiang Electronics plans to repurchase shares worth between 60 million to 100 million yuan [2] - Qilian Technology intends to raise no more than 182 million yuan through a private placement [2] - Jingu Co. signed a strategic cooperation agreement with Ninebot [1][2]

Core Viewpoint - The company is divesting its underperforming subsidiary, Shandong Lushang Yinzhu Commercial Management Co., Ltd., to optimize its asset structure and focus on its core businesses in pharmaceuticals and cosmetics [1][4]. Summary by Sections Transaction Details - The company plans to sell its 100% stake in the subsidiary for 88.4028 million yuan, which is less than a 1% premium over its net asset value [1]. - The subsidiary has reported cumulative losses of approximately 1.5 million yuan for the first half of 2024 and 2025 [1]. - The transaction is classified as a related party transaction, as both parties are controlled by the same parent company [1]. Financial Performance - The subsidiary's profitability has declined, with net profits of 33,000 yuan in 2022 and 479,100 yuan in 2023, followed by a net loss of 623,500 yuan in 2024 and 876,800 yuan in the first half of 2025 [2]. - The revenue of the subsidiary primarily comes from managing internal real estate projects, but it faces challenges due to policy changes affecting state-owned capital in the real estate sector [2]. Strategic Implications - The divestiture is part of the company's strategy to streamline operations and focus on its main sectors, which are pharmaceuticals and cosmetics, following the exit from the real estate business in 2023 [2][3]. - The company aims to concentrate resources on its core businesses to better compete in the market [2][3]. - The company reported a 7.05% decline in revenue to 1.79 billion yuan in the first half of 2025, with a net profit decrease of 15.16% to 108 million yuan [3]. Business Segment Performance - The cosmetics segment generated 1.094 billion yuan in revenue, down 7.73%, with mixed performance among core brands [3]. - The "Yilian" brand saw a revenue increase of 23.78% to 554 million yuan, while the "Aier Doctor" brand experienced a 29.97% decline to 451 million yuan [3]. - The pharmaceutical segment also faced challenges, with a 13.87% revenue decrease to 207 million yuan in the first half of 2025 [3].

Core Viewpoint - Furuida (600223.SH) announced a strategic development plan aimed at optimizing resource allocation and focusing on its core businesses in pharmaceuticals and cosmetics to enhance competitiveness and sustainable operational capacity [1] Group 1: Strategic Focus - The company plans to concentrate on its two main sectors: pharmaceuticals and cosmetics [1] - This strategic shift is intended to strengthen the company's competitive edge in the market [1] Group 2: Resource Allocation - The decision to optimize resource allocation is part of a broader strategy to improve operational efficiency [1] - The company aims to enhance its sustainable business capabilities through this resource reallocation [1]

Group 1 - The core point of the article is that Furuida plans to divest its 100% stake in Shandong Lushang Yinzou Commercial Management Co., Ltd. to focus on its main business and improve operational quality, with the transaction valued at 88.4028 million yuan [1] - After the transaction, Furuida will no longer hold any equity in Yinzou Commercial Management [1] - As of the first half of 2025, Furuida's revenue composition is as follows: cosmetics 61.13%, property leasing 16.37%, pharmaceuticals 11.57%, additives 9.98%, and other businesses 0.95% [1] Group 2 - Furuida's market capitalization is currently 7.9 billion yuan [2]

本资产评估报告依据中国资产评估准则编制 鲁商福瑞达医药股份有限公司 拟转让股权所涉及的 山东鲁商银座商业管理有限公司 股东全部权益价值 产评估报 鹏信资评报字[2025]第 S032 号 评估基准日:2024年12月31日 资产评估报告日:2025年03月18日 en Xin 深圳市鹏信资产评估土地房地产估价有限公司 SHENZHEN PENGXIN APPRAISAL LIMITED 中国广东省深圳市福田区福中路29号(彩田路口)福景大厦中座十四楼 Floor 14, Middle Block, Fujing Building, 29 Fuzhong Road, Futian District,Shenzhen, China 电话(Tel):+86755-8240 6288 直线(Dir):+86755-8240 3555 http://www.pengxin.com 传真(Fax):+86755-8242 0222 邮政编码(Postcode):518026 Email: px@pengxin.com 中国资产评估协会 备案回执生成日期:2025年03月19日 ICP备案号京ICP备2020034749号 ...

证券代码：600223 证券简称：福瑞达 编号：临 2025-030 鲁商福瑞达医药股份有限公司 关于转让全资子公司山东鲁商银座商业管理有限公司 100%股权暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 为聚焦主业发展，持续提升公司运行质量，鲁商福瑞达医药股份有限公司 （以下简称"公司"）拟将持有的山东鲁商银座商业管理有限公司（以下简称"银 座商管"）100%股权转让给鲁商福瑞达健康投资有限公司，交易价款依据评估值 确定为8,840.28万元。本次交易完成后，公司将不再持有银座商管的股权。 本次交易方鲁商福瑞达健康投资有限公司与公司为同受山东省商业集团 有限公司控制的公司，故本次交易构成关联交易。 本次交易未构成重大资产重组。 公司不存在为银座商管提供担保、委托理财，以及该公司占用上市公司资 金等方面的情况。 至本次关联交易为止，过去12个月内公司与同一关联人或与不同关联人之 间交易类别相同的关联交易未达到公司最近一期经审计净资产绝对值5%以上（不 含已履行相关程序的关联交易），本次关联 ...

法律意见书 国浩律师（济南）事务所 关于鲁商福瑞达医药股份有限公司 2025 年第一次临时股东会 之 济南市龙奥西路 1 号银丰财富广场 C 座 19、20、25 层 邮编：250014 19th-20th、25thFloor,BlockC,YinfengFortunePlaza,No.1Long'aoWestRoad,Jinan 电话/Tel:+8653186112118 传真/Fax:+8653186110945 网址/Website:http://www.grandall.com.cn 二〇二五年十月 国浩律师（济南）事务所（以下简称"本所"）接受鲁商福瑞达医药股份有 限公司（以下简称"福瑞达"或"公司"）的委托，指派本所律师林泽若明、张 灵君（以下简称"本所律师"）出席福瑞达 2025 年第一次临时股东会（以下简 称"本次股东会"），并出具本法律意见书。 为出具本法律意见书，本所律师出席了本次股东会，并依据《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简 称"《证券法》"）、《律师事务所从事证券法律业务管理办法》和《律师事务 所证券法律业务执业规则》等法律法规及规 ...

证券代码：600223 证券简称：福瑞达 公告编号：2025-029 鲁商福瑞达医药股份有限公司 2025年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 （一）股东会召开的时间：2025 年 10 月 10 日 （二）股东会召开的地点：山东省济南市高新区新泺大街 888 号公司会议室 （三）出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 604 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 577,748,396 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份 | | | 总数的比例（%） | 56.8331 | （四）表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况等。 本次股东会由公司董事会召集，会议由贾庆文先生主持。本次股东会采取现场投 票和网络投票相结合的方式进行表决。本次股东会的召集、召开及表决方 ...